|
On November 28, 2007 GeneraMedix Inc. received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Epirubicin Hydrochloride Injection. GeneraMedix will market Epirubicin Hydrochloride Injection, 2 mg/mL in 25 mL & 100 mL vials. The product is AP rated and equivalent to the brand Ellence® by Pfizer Inc.
For product information please contact:
GeneraMedix Inc. Customer Service
1-866–GENERA–1
(1-866-436-3721)
Ellence® is a registered trademark of Pfizer Inc.
|
